BioSyent Inc
Robert March has a diverse background in finance and accounting, with experience in various industries including pharmaceuticals, produce, transportation, insurance, robotics, and auditing. Robert currently serves as the Vice President and Chief Financial Officer at BioSyent Inc., a Specialty Pharmaceutical company. Robert has held leadership roles such as CFO and COO at Ippolito Group and CFO at Pinnacle Transportation. Robert also has experience as a Controller at Allianz Global Assistance Canada and Finance Manager at FANUC Robotics. With a CPA and CA designation, as well as an MBA and B.Sc. in Biochemistry, Microbiology and Immunology, Robert brings a strong financial acumen to their roles.
BioSyent Inc
1 followers
Listed on the TSX Venture Exchange (TSXV: RX) BioSyent is a profitable growth oriented speciality pharmaceutical company which searches the globe to in-license or acquire innovative pharmaceutical products that have been successfully developed, are proven safe and effective, and have track records of improving the lives of patients and supporting the healthcare professionals that treat them. Once a product of interest has been found, BioSyent acquires the exclusive rights to the product and manages it through the Canadian governmental regulatory approval process. Once approved, BioSyent markets the product throughout Canada. BioSyent continues to search for products to in-license or acquire that match the following criteria: - Are unique and occupy a niche in the market; - Provide novel technological or therapeutic advantages to patients and healthcare professionals; - Are backed by strong partners who hold defendable intellectual property rights. Backed by the success of our products, for two consecutive years (2012 & 2013) BioSyent was named to the TSX Venture Top 50 strong performing companies. BioSyent has been named one of Canada’s fastest growing companies by PROFIT Magazine.